- Syntex has elected three new board members appointed by the Roche group as part of its integration with the Swiss company. The Roche appointees are Armin Kessler, chief operating officer and head of Roche's pharmaceutical division, Peter Simon, head of the group's pharma operation and Kenneth Taylor, currently president and managing director of Roche Products in the UK. Meantime, resigning from the board were James Wilson, Dana Leavitt, Miriam Stoppard, Leonard Marks, Marvyn Carton, John Fried, Howard Holtzmann and Charles Lynch. The Syntex board elected Kenneth Taylor to succeed James Wilson as board president. Dr Taylor's successor in Roche UK will be Nic Holladay, the managing director of Syntex' UK and Ireland business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze